Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China

At the current WTP threshold in China, the combination of tislelizumab and chemotherapy may be cost-effective as a first-line treatment for patients with ES-SCLC.

Authors

Xiongxiong Fan
Zhengxiong Li (ORCID: https://orcid.org/0009-0000-6031-4755)
Dong Liu (ORCID: https://orcid.org/0000-0001-5498-6352)

Institutions

Xuzhou Medical College (CN)
Baoji City Central Hospital (CN)

Publication Details

Journal: Frontiers in Public Health
Published: 2025-10-14
DOI: https://doi.org/10.3389/fpubh.2025.1652917
Primary Topic: Lung Cancer Research Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China

Xiongxiong Fan, Zhengxiong Li, Dong Liu

Oct 14, 2025

Frontiers in Public Health

Lung Cancer Research Studies

article

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China

Xiongxiong Fan, Zhengxiong Li, Dong Liu

October 14, 2025article en

Abstract

At the current WTP threshold in China, the combination of tislelizumab and chemotherapy may be cost-effective as a first-line treatment for patients with ES-SCLC.

Frontiers in Public HealthVol. 13

Xuzhou Medical College (CN), Baoji City Central Hospital (CN)

Openalex Percentile: Top 61%

Lung Cancer Research Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China — Xiongxiong Fan, Zhengxiong Li, et al. · Frontiers in Public Health (2025) | TGRS Research Map | TGRS